News

Enlarge image

BusinessSwitzerland

Debiopharm licences Roche compound

09.01.2013 - Swiss Debiopharm Group (Lausanne) has licenced Chugai’s preclinical anti-cancer agent FF284.

The Tokyo-based Roche affiliate announced the deal on  8 January 2013, three weeks after the companies signed an agreement giving Debiopharm global rights to develop and commercialise the preclinical compound FF284 (now Debiopharm 1347).  Chugai remain the rights to the Japanese market.

Under the same agreement, Chugai will grant a non-exclusive license to develop and commercialise a companion diagnostic for FF284 (Debio 1347). According to the terms of the agreement, Debiopharm and the Roche daughter will conduct a Phase I dose escalation study. In return for the license, Chugai will receive an undisclosed upfront fee, milestone and royalty payments from Debiopharm.

Debio 1347 is an orally available small molecule targeting an undisclosed signalling pathway affecting solid tumour development

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2013-01/debiopharm-licences-roche-compound.html

AwardFinlandEU

27.05.2016 The Finnish Technology Academy has awarded US-American innovator Frances Arnold the 2016 Millennium Technology Prize, worth €1m. Arnold is a pioneer in the field of directed evolution.

OncologyUK

26.05.2016 BigDNA relaunches as Iceni Pharmaceuticals with the aim to develop repurposed and reformulated cancer therapies. First order of business: repurpose Merck Serono’s cilengitide as a multiple myeloma treatment.

MicrobiomeFranceDenmarkEU

24.05.2016 One of the pioneering companies developing pharmaceuticals and diagnostics based on the gut microbiome, Enterome Bioscience, has raised €14.5m in a Series C financing round. Among the investors were Seventure and Lundbeckfond as well as Nestlé.

AntibioticsEUUKItaly

20.05.2016 The long awaited global review on antimicrobial resistance by economist Lord Jim O’Neill has been published. It sets out an action plan to defeat superbugs with a huge awareness campaign and rapid diagnostics to be used before antibiotics are prescribed.

LicensingGermanyIrelandSwitzerland

18.05.2016 Bayer is deepening its involvement in CRISPR with a licensing agreement for genome editing patents. Irish partner ERS Genomics holds the rights to the CRISPR/Cas9 tech from Emmanuelle Charpentier, one of the inventors.

M&AGermany

17.05.2016 Newly rebranded Siemens Healthcare has entered the field of molecular testing for cancers with the acquisition of Cologne-based NEO New Oncology.

FinancingUK

11.05.2016 Newly spun out company OxStem has raised £16.9m (€21.5m) to develop regenerative meds for the treatment of age-related disease. It is the largest financing for an Oxford spin-out – or any UK academic spin-out – to date.

FinancingSwitzerland

09.05.2016 Swiss Genentech partner AC Immune has raised CHF42.7m (€38.6m) in order to advance its therapeutic and diagnostic product pipeline in Alzheimer’s disease. The news follows a recently announced R&D collaboration with Biogen.

FinancingSpain

04.05.2016 Barcelona-based epigenetics expert Oryzon Genomics has closed a debt funding round of €10.5m, bringing the total money raised since last year to €27m. The funds will serve to advance the company’s two LSD1 inhibitors in cancer and neurodegeneration.

Open InnovationFrance

03.05.2016 Ipsen is strengthening its ties to long-time development partner Oncodesign, a Dijon-based cancer treatment biotech. The French pharma is handing over the pre-clinical pharmacology for its oncology research programmes to Oncodesign.

Quick news provided by GlobeNewswire

View more stock news

Events

All Events

Partner-Events

Aachen

Biomedica 2016

Basel (CH)

Chemspec Europe 2016

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • BIOTIE THERAPEUTICS (FI)0.27 EUR92.86%
  • PLETHORA (UK)3.38 GBP12.67%
  • ALMIRALL (E)14.43 EUR7.93%

FLOP

  • 4SC (D)2.59 EUR-20.31%
  • NEUROVIVE PHARMACEUTICAL AB (S)5.25 SEK-4.55%
  • FORMYCON (D)20.15 EUR-4.37%

TOP

  • GALAPAGOS (B)51.86 EUR30.6%
  • NICOX (F)11.00 EUR26.0%
  • GENMAB (DK)1177.00 DKK21.2%

FLOP

  • 4SC (D)2.59 EUR-24.5%
  • MOBERG PHARMA (S)38.00 SEK-23.1%
  • BIONOR PHARMA (N)0.68 NOK-20.0%

TOP

  • CHRONTECH PHARMA (S)0.34 SEK3300.0%
  • KARO BIO (S)30.60 SEK1913.2%
  • NICOX (F)11.00 EUR485.1%

FLOP

  • NEUROVIVE PHARMACEUTICAL AB (S)5.25 SEK-89.1%
  • BB BIOTECH (D)44.03 EUR-84.7%
  • BIOTEST (D)17.15 EUR-78.0%

No liability assumed, Date: 27.05.2016